Q2 2021 13F Holders as of 30 Jun 2021
-
Type / Class
-
Equity / Common Stock, par value $0.00001
-
Shares outstanding
-
62,162,717
-
Total 13F shares
-
47,991,159
-
Share change
-
+3,843,884
-
Total reported value
-
$2,154,086,054
-
Put/Call ratio
-
223%
-
Price per share
-
$44.88
-
Number of holders
-
136
-
Value change
-
+$180,239,014
-
Number of buys
-
80
-
Number of sells
-
49
Institutional Holders of Protagonist Therapeutics, Inc - Common Stock, par value $0.00001 (PTGX) as of Q2 2021
As of 30 Jun 2021,
Protagonist Therapeutics, Inc - Common Stock, par value $0.00001 (PTGX) was held by
136 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
47,991,159 shares.
The largest 10 holders included
FMR LLC, BVF INC/IL, RTW INVESTMENTS, LP, Consonance Capital Management LP, BlackRock Inc., Johnson & Johnson Innovation - JJDC, Inc., Farallon Capital Management LLC, VANGUARD GROUP INC, STATE STREET CORP, and DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C).
This page lists
136
institutional shareholders reporting positions in this security
for the Q2 2021 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.